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“Ending AIDS” by 2030 is a monumental challenge [1]. Tracking progress as incidence reaches 
lower levels may be just as challenging. Nsanzimana and colleagues illustrate progress and 
highlight the challenges that lie ahead on both fronts.  The Rwanda HIV Incidence Survey 
enumerated a nationally representative sample of 13,728 HIV-negative adults in 2013, and 
followed up a remarkable 92% of participants one year later. They observed 35 HIV 
seroconversions [2]. Two findings are especially noteworthy. First, estimated annual HIV 
incidence in 2013 was 0.27% (95% confidence interval 0.18–0.36%), almost twice as high as 
the 0.15% (0.11–0.19%) incidence estimate published in the UNAIDS 2016 Global Report [3], 
derived using the Spectrum model [4]. Second, the study suggests clusters of new infection 
responsible for sustaining HIV transmission, with the few new infections clustered in three 
villages and two households having multiple seroconversions. We consider implications of these 
findings for future surveillance efforts and the HIV response.   
What might explain the difference between cohort study and model-based incidence estimates? 
The wide uncertainty ranges around each estimate remind us that uncertainty is an inherent 
feature of our estimates that must be recognized by policy processes. For example, at the 
higher transmission level, Rwanda may need to initiate around 75,000 more adults on ART 
between 2015 and 2020 to reach 90% coverage, compared to 45,000 if transmission levels are 
more aligned with the lower figure (see Figure 1). Resource allocation plans will need to 
accommodate the full range of plausible scenarios and surveillance efforts must be oriented 
towards determining which trajectory we are on and how to respond. 
Both sources of information have potential error. Cohort studies may experience participation 
biases. Alternatively, the presence of just 16 false positive results among over 12,000 tests 
undertaken at follow-up (reflecting a specificity of 99.9%) would fully explain the difference 
between survey and model estimates. Participation rates were high and there are no particular 
reasons to suspect the testing accuracy in this study, but this does reinforce the importance of 
critically appraising and triangulating data sources, especially when detecting increasingly rare 
events.  
On the other hand, the model enforces an intrinsic relationship between the number of new HIV 
infections, the number of HIV deaths, and changes in HIV prevalence. Have there been more 
deaths than previously thought, counterbalancing the higher than expected number of new 
infections suggested by the cohort study?  Nsanzimana and colleagues have previously 
reported a crude mortality rate on ART around 1% in 2013 [5], similar to the Spectrum model 
estimates, suggesting this may be unlikely. Alternatively, has prevalence increased more than 
previously thought, despite a series of prevalence surveys suggesting this has been stable at 
3.0% since 2010 [2,6,7]? Our best information likely comes from appropriately combining all the 
data we have (e.g. prevalence trends, mortality estimates, incidence data). New data provide a 
critical opportunity to review, validate, and improve the assumptions underpinning future model 
projections for Rwanda, and for other countries that use the same tools [8].  
The new study suggests that localised outbreaks may now be an important feature of the HIV 
epidemic in Rwanda. Halting the epidemic will increasingly depend on rapidly identifying, 
characterizing, and stopping transmission clusters. This requires a re-tooled surveillance 
portfolio that includes risk mapping to know where and among whom transmission clusters 
might emerge [9], careful monitoring of new diagnoses across all HIV testing platforms [10,11], 
and the roll-out of new surveillance and public health tools such as incidence assays and 
phylogenetic sequencing to characterize transmission [12].  
These findings underscore that further studies of the type conducted by Nsanzimana and 
colleagues are essential to improve our understanding of HIV dynamics in Rwanda and beyond. 
But the study also reminds us that, as incidence declines, measuring and accelerating progress 
towards ending AIDS will depend on how quickly we can determine and respond to new HIV 
infections in 2017 and beyond. This will require new types of data analysed with new models to 
rapidly identify where, when, and why HIV transmission occurs. We must be ready to use this 
information to trigger a timely, data-driven public health response if we are to continue to drive 
down HIV incidence.  
  
Figure: Projected HIV incidence, HIV prevalence, and cumulative number of ART initiations 
required to reach 90% coverage by 2020 under two assumptions about future HIV transmission. 
Assuming ART coverage of 63% in 2013 and 82% viral suppression among those on treatment 
[5], an incidence rate of 0.27% in 2013 (consistent with the Rwanda incidence survey) implies 
that each 1000 unsuppressed HIV-positive adults generated 15 new HIV infections per year, 
compared to 8 new infections per year if incidence was 0.15% (consistent with the model 
estimate). Numbers of new infections are projected assuming that untreated adults continue to 
transmit HIV at these same rates (no other prevention interventions are modelled). ART 
coverage is assumed to scale-up linearly from 75% to 90% over the period 2015 to 2020 and 
viral suppression among PLHIV is assumed to scale up linearly from 82% [5] to 90% from 2015 
to 2020. In both cases, incidence is expected to continue declining as progress continues 
towards achieving national 90% coverage and viral suppression targets in 2020, but the 
remaining incidence rate in 2020 will be higher, and prevalence will be higher in 2020 owing to 
the higher number of new infections, resulting in greater numbers requiring treatment to reach 
90% coverage targets.  
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